| prescription drugs sleep canadian online pharmacy without prescription online pain medicine prescription drugs for high blood pressure hemorrhoid ointment mercury drugstore cost online pharmacy degree florida boots chemist online drugstore pain relief for dogs ibuprofen chronic pain management clinics generic pain pills pain management sickle cell anemia massage pain relief enbrel rheumatoid arthritis treatment importing prescription drugs into otc pain medication dogs drug store locator deltoid muscle pain treatment tooth pain medicine best drugstore mineral makeup drug store news continuing education medwell physicians surgeon pain management knee pain relief more alternative medicine pediatric pain management guidelines upper back muscle pain treatment Pain Relief Drugs Labour |
Ivan Gergel, M.D., Endo's executive vice president of research and development, stated. More information, including this and past of Endo Pharmaceuticals, is available at. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration CHADDS FORD, Pa., / - / -- Endo Pharmaceuticals (Nasdaq. "As a result of our ongoing antibiotic rash in fish drug storestrategic review initiated last year, we have terminated certain research and development programs. Safe Harbor Statement This contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In the meantime, we remain drug storecommitted to building our pipeline by pursuing programs at all phases of development, including potential products arising from our virtual discovery program." Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale chemistand marketing tab tetracyclineof branded and generic prescription pharmaceuticals used primarily to treat and manage pain. The forward-looking statements in this and on the related conference call are qualified by these risk factors. Risks and uncertainties include online pharmacistthe satisfaction of closing conditions for the acquisition, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act; the tender of a majority of the outstanding shares of com stock of Indevus; the possibility that the transaction will not be completed, or if completed, cipralex and green teanot completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the potential that market segment growth pain treatmentwill not follow historical patterns; general industry conditions and competition; business and economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents citalopram tabletsattained by competitors; challenges inherent in new product development, including obtaining regulatory online pharmacistapprovals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including butalbital apap caffeineour current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly online pharmacy reviews hydrocodonethe discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K/A for the year ended , which was filed with the Securities and Exchange Commission on. pain managementIn 2007, Endo licensed exclusive rights to develop and commercialize AZ-003 in North America. The product, Staccato(R) fentanyl (AZ-003/EN-3284), has completed emergency contraceptivesPhase I clinical testing and will be returned to Alexza. ENDP) announced today that by mutual agreement it has concluded its arthritis treatmentresearch collaboration with Alexza Pharmaceuticals, Inc. Its products include LIDODERM(R), a topical patch to relieve the pain amoxicillin express chemistof postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the effexor withdrawal symptomsrelief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis drugstoreof joints amenable to topical treatment. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. narcotic pain killersWe assume no obligation to publicly update any forward-looking statements, whether as a result of new prescription medicationinformation, future developments or otherwise.. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this. ALXA) to develop an inhaled fentanyl product for the treatment of breakthrough pain using Alexza's Staccato(R) inhalation technology. We have enjoyed working with Alexza and wish them success with their drug development programs. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. |
|
 | |||||||||||||||||||||||||||||||||
